Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 5,846.2 | 4,347.5 | 4,108.4 | 4,120.9 | 3,802.2 | 4,488.5 | 3,780.2 | 3,838.7 |
| Revenue growth | 34.5% | 5.8% | -0.3% | 8.4% | -15.3% | 18.7% | -1.5% | 6.6% |
| Cost of goods sold | 4,180.2 | 3,134.5 | 2,987.4 | 3,073.9 | 2,853.6 | 3,256.1 | 2,720.2 | 2,801.9 |
| Gross profit | 1,666.0 | 1,213.0 | 1,121.0 | 1,047.0 | 948.6 | 1,232.4 | 1,060.0 | 1,036.8 |
| Gross margin | 28.5% | 27.9% | 27.3% | 25.4% | 24.9% | 27.5% | 28.0% | 27.0% |
| Selling, general and administrative | 697.8 | 543.7 | 509.6 | 515.2 | 458.1 | 598.1 | 527.8 | 556.6 |
| Research and development | 154.5 | 125.9 | 121.6 | 121.5 | 111.6 | 139.2 | 113.9 | 119.6 |
| EBITA | 851.2 | 576.8 | 217.1 | 378.0 | 242.5 | 545.7 | 420.3 | 361.1 |
| EBITA margin | 14.6% | 13.3% | 5.3% | 9.2% | 6.4% | 12.2% | 11.1% | 9.4% |
| Amortization of intangibles | 36.0 | 31.9 | 31.6 | 14.8 | 2.7 | 6.8 | 3.0 | 2.9 |
| EBIT | 815.2 | 544.9 | 185.5 | 363.2 | 239.8 | 538.9 | 417.3 | 358.2 |
| EBIT margin | 13.9% | 12.5% | 4.5% | 8.8% | 6.3% | 12.0% | 11.0% | 9.3% |
| Pre-tax income | 736.4 | 472.7 | 110.7 | 310.7 | 212.9 | 389.7 | 314.8 | 287.9 |
| Income taxes | 141.0 | 98.0 | 80.3 | 57.3 | 111.6 | 115.3 | 83.9 | 93.0 |
| Tax rate | 19.1% | 20.7% | 72.5% | 18.4% | 52.4% | 29.6% | 26.7% | 32.3% |
| Earnings from continuing ops | 595.4 | 374.7 | 30.4 | 253.4 | 101.3 | 274.4 | 230.9 | 194.9 |
| Earnings from discontinued ops | -2.1 | -2.0 | -161.4 | 11.9 | 45.1 | 1.6 | 23.3 | 103.4 |
| Net income | 593.3 | 372.7 | -131.0 | 265.3 | 146.4 | 276.0 | 241.4 | 245.7 |
| Net margin | 10.1% | 8.6% | -3.2% | 6.4% | 3.9% | 6.1% | 6.4% | 6.4% |
| |
| Diluted EPS | $7.59 | $4.70 | $0.36 | $2.87 | $1.12 | $2.98 | $2.45 | $2.05 |
| Shares outstanding (diluted) | 78.4 | 79.7 | 85.6 | 88.2 | 90.1 | 92.0 | 94.3 | 95.1 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|